Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Beth Rutland

Anatomic Pathology & Clinical Pathology Mobile, AL Medical Doctor

NPI 1710079835 CMS profile 611156

2451 Fillingim St, Mastin 617, Mobile, AL 36617

Open in the dashboard

General payments

$6,671

301 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Beth Rutland of Mobile, AL is reported in the CMS Open Payments database as having received $6,671 across 301 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Anatomic Pathology & Clinical Pathology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $755 30
2024 General $1,088 38
2023 General $940 34
2022 General $1,100 49
2021 General $1,393 65
2020 General $500 31
2019 General $896 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Beth Rutland
  • Anatomic Pathology & Clinical Pathology median
  • Middle half of Anatomic Pathology & Clinical Pathology
  • National median

In program year 2025, general payments to Beth Rutland were reported at $755. Among 2,804 Anatomic Pathology & Clinical Pathology profiles paid that year, the median was $51 and the middle half received between $24 and $149.

Show as a table
Year Beth Rutland Anatomic Pathology & Clinical Pathology median Middle half National median
2019 $896 $65 $22–$150 $163
2020 $500 $44 $19–$144 $114
2021 $1,393 $42 $19–$142 $132
2022 $1,100 $54 $20–$140 $149
2023 $940 $60 $23–$157 $160
2024 $1,088 $51 $23–$145 $164
2025 $755 $51 $24–$149 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $1,139 76 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $946 57 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $669 44 payments
  4. AbbVie, Inc. $422 16 payments
  5. Janssen Scientific Affairs, LLC $356 3 payments
  6. Genzyme Corporation $326 6 payments
  7. Phathom Pharmaceuticals, Inc. $305 6 payments
  8. Boston Scientific Corporation $213 3 payments
  9. E.R. Squibb & Sons, L.L.C. $206 2 payments
  10. Nestle HealthCare Nutrition Inc. $194 11 payments
  11. Other $1,896 77 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,671 301 payments
Products named General payments · program years 2019–2025
  1. STELARA $1,376 73 payments
  2. TRULANCE $525 30 payments
  3. ENTYVIO $367 21 payments
  4. ZENPEP $361 20 payments
  5. SIMPONI $339 26 payments
  6. DUPIXENT $326 6 payments
  7. VOQUEZNA $276 4 payments
  8. XIFAXAN $251 14 payments
  9. SIMPONI ARIA $251 16 payments
  10. REMICADE $251 16 payments
  11. Other $3,492 139 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

301 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record